Adjunctive antipsychotic in the treatment of body dysmorphic disorder – A retrospective naturalistic case note study

References

• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders (Fifth edition). Arlington, VA: American Psychiatric Publishing.
   Google Scholar
• Bjornsson AS, Didie Elizabeth R, Phillips Katherine A. 2010. Body dysmorphic disorder. Dialogues Clin Neurosci 12:221–232.
   PubMedGoogle Scholar
• Deckersbach T, Savage CR, Phillips KA, Wilhelm S, Buhlmann U, Rauch SL, et al. 2000. Characteristics of memory dysfunction in body dysmorphic disorder. J Int Neuropsychol Soc 6:673–681.
   PubMed Web of Science ®Google Scholar
• Eisen JL, Phillips KA, Coles ME, Rasmussen SA. 2004. Insight in obsessive compulsive disorder and body dysmorphic disorder. Comp Psychiatry 45:10–15.
   PubMed Web of Science ®Google Scholar
• Fallon BA. 2004. Pharmacotherapy of somatoform disorders. J Psychosom Res 56:455–446.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Brown A, Reghunandanan S, Pampaloni I 2012. Evidence-based pharmacotherapy of obsessive compulsive disorder. Int J Neuropsychopharmacol 15:1173–1191.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. 1989. The Yale–Brown Obsessive–Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011.
   PubMed Web of Science ®Google Scholar
• Grant JE. 2001. Successful treatment of non delusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry 62:297–298.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Crow SJ. 2001. Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. J Clin Psychiatry 62:517–522.
   PubMed Web of Science ®Google Scholar
• Grant JE, Phillips KA. 2005. Recognizing and treating body dysmorphic disorder. Ann Clinical Psychiatry 17:205–210.
   PubMedGoogle Scholar
• Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. 1999. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56:1033–1039.
   PubMed Web of Science ®Google Scholar
• Mufaddel A, Osman OT, Almugaddam F, Jafferany M. 2013. A review of body dysmorphic disorder and its presentation in different clinical settings. Prime Care Companion CNS Disord 15:PCC.12r01464.
   Google Scholar
• Munro A, Chmara J. 1982. Monosymptomatic hypochondriacal psychosis: a diagnostic checklist based on 50 cases of the disorder. Can J Psychiatry 27:374–376.
   PubMedGoogle Scholar
• Neziroglu F, Khemlani-Patel S. 2002. A review of cognitive and behavioral treatment for body dysmorphic disorder. CNS Spectr 7:464–471.
   PubMedGoogle Scholar
• Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. 1996. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 11:247–254.
   PubMedGoogle Scholar
• Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. 1993. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 150:302–308.
   PubMed Web of Science ®Google Scholar
• Phillips KA. 1996. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull 32:597–605.
   PubMedGoogle Scholar
• Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. 1997. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 33:17–22.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Dwight MM, McElroy SL. 1998. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 59:165–171.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. 2001. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 62:721–727.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Najar F. 2003. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 64:715–720.
   PubMed Web of Science ®Google Scholar
• Phillips KA. 2005a. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 162:377–379.
   PubMed Web of Science ®Google Scholar
• Phillips KA 2005b. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 162:5.
   Google Scholar
• Nakaaki S, Murata Y, Furukawa TA. 2008. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder Psychiatry Clin Neurosci 62: 370.
   Google Scholar
• Taylor D, Paton C, Kapur S 2012. The maudsley prescribing guidelines in psychiatry, 11th edition. Chichester: Wiley-Blackwell.
   Google Scholar
• Uzun O, Ozdemir B 2010. Aripiprazole as an augmentation agent in treatment resistant body dysmorphic disorder: a case report Clin Drug Investig 30:707–710.
   PubMed Web of Science ®Google Scholar
• Veale D, Boockock A, Gournay K, Dryden W, Shah F, Wilson R, Walburn J. 1996. Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry 169:96–201.
   Google Scholar
• Veale D. 2000. Outcome of cosmetic surgery and ‘DIY’ surgery in patients with body dysmorphic disorder. Psychiatr Bull 24: 218–220.
   Google Scholar
• Wilhelm S, Otto MW, Zucker BG, Pollack MH: 1997. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord 11:499–502.
   PubMed Web of Science ®Google Scholar